DEBIO 9902
Alternative Names: DEBIO 9902 SR; DEBIO-9902 SR implants; N-(5-chloro-2-hydroxy-3-methoxy-benzylidene)-huperzine A; Oral ZT 1; ZT 1 Long Acting; ZT 1 sustained-release SC implant; ZT-1; ZT-1 LALatest Information Update: 16 Aug 2010
At a glance
- Originator Chinese Academy of Sciences; Jiangsu Yangtze Pharma
- Developer Debiopharm
- Class Alkaloids; Antidementias; Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 23 Oct 2008 Debiopharm Group completes phase II (BRAINz) trial in Alzheimer's disease
- 21 Oct 2008 Phase-I clinical trials in Alzheimer's disease of new tablet formulation in healthly elderly volunteers in USA (PO)
- 06 Mar 2008 The phase II (BRAINz) trial is ongoing for Alzheimer's disease